Abstract
Nowadays, infections with Candida albicans (C.a.) are very frequent, mostly in the so-called immunocompromised host. Therefore, research has been focused on the types of immune response elicited by C.a., with the aim to develop novel therapeutic strategies. Neutrophils and macrophages (Mφ) are deeply involved in the host defense against C.a., and also dendritic cells (DCs) seem to be very active in the host protection. In particular, DCs display an array of surface receptors able to interact with fungal components, even including Toll-like receptors. Here, we will illustrate the in vitro immune response of human monocyte-derived DCs infected with C.a. . In this test system, DCs exert phagocytic and killing activities with a magnitude similar to that of Mφ. Moreover, in the presence of autologous CD4+ cells, DCs produce T-helper (h) 1 type cytokines. This Th1 polarizing activity is mediated by interleukin- 12 released by infected CDs in the presence of CD4+ cells. Taken together, these data suggest a protective role played by DCs in the course of C.a. infection and the possibility to develop new strategies of immune intervention.
Keywords: phagocytosis, C. albicans-Infected DCs, monocytes-macrophage, progesterone, immunity
Current Pharmaceutical Design
Title: In Vitro Infection of Human Monocyte-Derived Dendritic Cells with Candida albicans: Receptorial Involvement and Therapeutic Implications
Volume: 12 Issue: 32
Author(s): Maria Pepe, Emilio Jirillo and Vito Covelli
Affiliation:
Keywords: phagocytosis, C. albicans-Infected DCs, monocytes-macrophage, progesterone, immunity
Abstract: Nowadays, infections with Candida albicans (C.a.) are very frequent, mostly in the so-called immunocompromised host. Therefore, research has been focused on the types of immune response elicited by C.a., with the aim to develop novel therapeutic strategies. Neutrophils and macrophages (Mφ) are deeply involved in the host defense against C.a., and also dendritic cells (DCs) seem to be very active in the host protection. In particular, DCs display an array of surface receptors able to interact with fungal components, even including Toll-like receptors. Here, we will illustrate the in vitro immune response of human monocyte-derived DCs infected with C.a. . In this test system, DCs exert phagocytic and killing activities with a magnitude similar to that of Mφ. Moreover, in the presence of autologous CD4+ cells, DCs produce T-helper (h) 1 type cytokines. This Th1 polarizing activity is mediated by interleukin- 12 released by infected CDs in the presence of CD4+ cells. Taken together, these data suggest a protective role played by DCs in the course of C.a. infection and the possibility to develop new strategies of immune intervention.
Export Options
About this article
Cite this article as:
Pepe Maria, Jirillo Emilio and Covelli Vito, In Vitro Infection of Human Monocyte-Derived Dendritic Cells with Candida albicans: Receptorial Involvement and Therapeutic Implications, Current Pharmaceutical Design 2006; 12 (32) . https://dx.doi.org/10.2174/138161206778743592
DOI https://dx.doi.org/10.2174/138161206778743592 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Electrochemical Measurement of Antidiabetic Potential of Medicinal Plants Using Screen-printed Carbon Nanotubes Electrode
Current Nanoscience Meet Our Editorial Board Member:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Selections:
Recent Patents on Biomarkers Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design Management of Obesity in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Application of Aptamer-based Hybrid Molecules in Early Diagnosis and Treatment of Diabetes Mellitus: From the Concepts Towards the Future
Current Diabetes Reviews Hydrogen Sulfide in Diabetic Complications: Focus on Molecular Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical Composition and <i>In vitro</i> Antidiabetic Effects of <i>Olea europaea</i> Linn. (Olive)
Current Bioactive Compounds Role of Brain NUCB2/nesfatin-1 in the Stress-induced Modulation of Gastrointestinal Functions
Current Neuropharmacology Carotid Intima Media-thickness and Genes Involved in Lipid Metabolism in Diabetic Patients using Statins – a Pathway Toward Personalized Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Abietane Diterpenes as Potential Candidates for the Management of Type 2 Diabetes
Current Pharmaceutical Design